Anti-inflammatory Disease Therapies
Sarah Bolton(AstraZeneca (United Kingdom)), Aude Roulois(GlaxoSmithKline (United Kingdom)), Jeffrey K. Huang(Georgetown University), Joel D. Parry(Age UK), Dave Hassall(GlaxoSmithKline (United Kingdom)), Rajni Fagg(GlaxoSmithKline (United Kingdom)), Mary McFarlane, Tom P. McKevitt(GlaxoSmithKline (United Kingdom)), Stefano Pluchino(University of Cambridge), Deon Hildebrand(GlaxoSmithKline (United Kingdom)), Wolfgang Brück(Universitätsmedizin Göttingen)
Cited by 2
Related Papers
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis
|Brain|2007|714
Association between pathological and MRI findings in multiple sclerosis
|The Lancet Neurology|2012|484
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange
|The Lancet|2005|430
Remyelinated Lesions in Multiple Sclerosis
|Archives of Neurology|2003|326